Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score.

Iino C, Abe T, Endo K, Fujiwara Y, Yoshida K, Sato S, Numao H, Igarashi G, Oikawa T, Ninomiya M, Tsuruoka M, Sato W, Minami S, Abe K, Fujita M, Tanabe N, Katsumi T, Maki K, Suda G, Sho T, Yamamoto Y, Baba M, Meguro T, Sakuraba H, Sakamoto N, Ueno Y, Kuroda H, NORTH Japan HCC Study Group

DOI: 10.3390/cancers18203366

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.